Skip to main content

#UK, #England: Notified cases of invasive #meningococcal disease - Updated 23 March 2026 (UKHSA, edited)

 


{Excerpt}

(...)

Daily case figures

-- The number of confirmed and probable cases can change when:

- a case is laboratory confirmed

- when the clinical assessment changes, including when new laboratory results are available

- when further epidemiological information is available

-- The figures in Table 1 cannot be used to identify the number of new confirmed or probable cases from one day to the next. This also applies to total cases.


Table 1. Cases of invasive meningococcal disease linked to Canterbury, Kent by day from 16 March 2026

[Date - Total confirmed cases - Confirmed MenB cases (subset of total confirmed cases) - Probable cases - Total cases]

* 22 March 2026 - 20 [note 2] - 19 -9 - 29

* 21 March 2026 - 20 [note 2] - 19 - 9 - 29

* 20 March 2026 - 23 - 18 - 11 - 34

* 19 March 2026 - 18 - 13 - 11 - 29

* 18 March 2026 - 15 - 9 - 12 - 27

* 17 March 2026 - 9 - 6 - 11 - 20

* 16 March 2026 - [note 1] - 4 - [note 1] - 15

__

Note 1: The distinction between a confirmed case and a probable case was not reported

Note 2: A case initially classified as a confirmed case may be reclassified or discarded when further laboratory results and clinical information is available. This applies to situations where:

- there are other negative results, for example, reference unit results 

and 

- there is an alternative diagnosis or where the clinical picture is no longer consistent with meningococcal infection

__

Note: The case numbers presented in Table 1 were confirmed at specific times of day for each of the releases: 16 March 2026 verified at 5:00pm, 17 March 2026 verified at 3:00pm, 18 March 2026 onwards verified at 12:30pm.

-- There have been 2 deaths since the start of the incident.

(...)

Source: 


Link: https://www.gov.uk/government/publications/invasive-meningococcal-disease-statistical-releases/notified-cases-of-invasive-meningococcal-disease

____

Comments

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...